Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Why CRISPR Therapeutics Stock Rocked the Market Last Month
4+ day, 4+ hour ago (556+ words) The FDA-approved drug it helped developed saw a nearly 80% sequential rise in sales. It also booked $10 million in upfront payments with a business partner. Pioneering gene-editing company CRISPR Therapeutics(NASDAQ: CRSP) was a well-performing biotech stock in August. Its shares…...
One Swim at a Time: Using Fish to Understand Psychoactive Drugs
5+ day, 15+ hour ago (13+ words) Toledo Blade...
Eli Lilly Just Announced a Major Acquisition. Here's What It Means.
1+ week, 3+ day ago (196+ words) Lilly has acquired some 26 companies since 2023. Sales of its GLP-1 drug are funding the deals. This week, Eli Lilly(NYSE: LLY) announced a deal that will add to its already formidable drug pipeline. The company's leading therapy, MER511, is in Phase…...
Intelligent Bio Solutions Issues Routine Investor Presentation Update
2+ week, 4+ hour ago (152+ words) Intelligent Bio Solutions ( (INBS) ) has provided an announcement. Spark’s Take on INBS Stock According to Spark, TipRanks’ AI Analyst, INBS is a Neutral. The score is held down primarily by weak financial performance (large losses, declining gross margin, and heavy…...
Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting
2+ week, 3+ day ago (380+ words) Gilead reported big losses last quarter, but this could pave the way for its diversification into oncology. In the meantime, investors remain focused mostly on the main growth driver: HIV prevention medicines. Based on 2027 earnings forecasts, this stock may have…...
Opinion | ‘Science fiction’: Five writers share what medical innovation excites them most
2+ week, 3+ day ago (84+ words) ‘Science fiction’: Five writers share what medical innovation excites them most The Washington Post New technology is enabling major advances in medicine. Last week, drugmakers Moderna and Merck announced promising Phase 3 trial results for what could be a major leap…...
ADS-B 'In' Developments Advance Ahead Of Potential Mandates
2+ week, 4+ day ago (54+ words) Aviation Week ADS-B 'In' Developments Advance Ahead Of Potential Mandates American Airlines is undergoing ACSS’ largest installation to date of its SafeRoute+ ADS-B In system. ADS-B 'In' Developments Advance Ahead Of Potential Mandates is part of our Aviation Week & Space…...
Report: Mass. biopharma is bouncing back. But the jobs haven’t yet.
2+ week, 4+ day ago (416+ words) Massachusetts’ biopharma industry is showing signs of a comeback, but its workforce is still feeling the effects of the downturn. Employment in the state’s biopharma sector fell 3.1% in 2025, or about 3,600 jobs, marking the first annual decline in more than two…...
Syngenis banks R&D refund to fuel biotech build-out
2+ week, 5+ day ago (521+ words) August 25, 2026 — 9:05am Australian biotechnology company Syngenis Labs has received a $363,000 research and development tax refund, adding another shot of non-dilutive capital to its genetic medicine ambitions. The refund lands shortly after the company closed an oversubscribed $4 million pre-IPO raise through Euroz…...
Symbiotec Pharmalab gets Rs 526 crore anchor backing ahead of IPO; Citi Group, Singularity among investors
3+ week, 1+ day ago (368+ words) The Economic Times Pharmaceutical and biotechnology company Symbiotec Pharmalab has raised Rs 526.20 crore from anchor investors ahead of its initial public offering (IPO), which opens for public subscription on August 24, 2026 Through the public issue, the company seeks to raise Rs…...